---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-101741"
form_type: "8-K"
ticker: "CTXR"
cik: "0001506251"
company_name: "Citius Pharmaceuticals, Inc."
filed_at: "2025-10-23T23:59:59+00:00"
generated_at: "2026-05-17T02:29:47.393605+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "medium"
source: SEC EDGAR
---

# Citius Pharmaceuticals updates corporate presentation; reiterates LYMPHIR Q4 2025 launch and pipeline progress

## Summary
- LYMPHIR (denileukin diftitox-cxdl) FDA approved for CTCL; commercial launch planned Q4 2025.
- Mino-Lok Phase 3 completed with positive topline data meeting primary and secondary endpoints.
- Halo-Lido Phase 2b completed; only prescription therapy under development for hemorrhoids.
- Citius Oncology (CTOR) spun off August 2024; CTXR intends to distribute CTOR shares to CTXR shareholders.
- Over $90M invested in LYMPHIR; new J-code (J9161) and NCCN guidelines inclusion secured.

## SEC filing metadata
- accession: 0001213900-25-101741
- form_type: 8-K
- ticker: CTXR
- cik: 0001506251
- company_name: Citius Pharmaceuticals, Inc.
- filed_at: 2025-10-23T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: medium
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1506251/000121390025101741/0001213900-25-101741-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1506251/000121390025101741/ea0262321-8k_citius.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-101741
- JSON: https://secwatch.observer/filing/0001213900-25-101741.json
- Plain text: https://secwatch.observer/filing/0001213900-25-101741.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.